Navigation Links
Immunotech Laboratories Announces South American Strategy
Date:4/3/2009

GLENDALE, Calif., April 3 /PRNewswire-FirstCall/ -- Immunotech Laboratories (Pink Sheets: IMMB) is happy to announce preliminary discussions in setting up a potential venture for South America, headquartered in Mexico.

According to Ara Ghanime, Chairman of Immunotech Laboratories, the potential outcome from these discussions, will enhance the company's efforts for its preclinical activities and position the company for a viable regional market penetration. Additional information will be provided as the company continues to implement its South American strategy. Immunotech's management is committed to bring its corporate mission to fruition utilizing its novel therapeutic platform of Irreversible Pepsin Fraction (IPF) for the treatment of HIV/AIDS.

Furthermore, Immunotech Laboratories would like to clarify an editorial error in our press release dated April 1, 2009. Mr. David Miller was stated as "and founder of ACT UP HIV/AIDS activist group". The correct information should have stated Mr. Miller as being one of the many founders of ACT UP. We apologize for this error and any inconvenience that this may have caused.

This news release contains forward-looking statements that involve risks and uncertainties associated with financial projections, budgets, milestone timelines, clinical development, regulatory approvals, and other risks described by Immunotech Laboratories, Inc. from time to time in its periodic reports filed with the SEC. IPF is not approved by the US Food and Drug Administration or by any comparable regulatory agencies elsewhere in the world. While Immunotech Laboratories believes that the forward-looking statements and underlying assumptions contained therein are reasonable, any of the assumptions could be inaccurate, including, but not limited to, the ability of Immunotech Laboratories to establish the efficacy of IPF in the treatment of any disease or health condition, the development of studies and strategies leading to commercialization of IPF in the United States, the obtaining of funding required to carry out the development plan, the completion of studies and tests on time or at all, and the successful outcome of such studies or tests. Therefore, there can be no assurance that the forward-looking statements included in this release will prove to be accurate. In light of the significant uncertainties inherent in the forward-looking statements included herein, Immunotech Laboratories or any other person that the objectives and plans of Immunotech Laboratories will be achieved should not regard the forward-looking statements as a representation.


'/>"/>
SOURCE Immunotech Laboratories, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Shire Files Lawsuit Against Barr Laboratories for Infringement of FOSRENOL(R) (Lanthanum Carbonate) Patents
2. Frontage Laboratories Continues to Grow Its China Business and Add Corporate Financial, Regulatory and Clinical Pharmacology Talent
3. Shire Receives FOSRENOL Paragraph IV Notice Letters from Barr Laboratories and Mylan
4. Pacific Northwest National Laboratories Becomes a GeneGo Center of Excellence
5. Adecco Receives Honor From Alcon Laboratories
6. ETS Laboratories Offers New Process Optimization Tools to the Fuel Ethanol Industry
7. Caraco Pharmaceutical Laboratories, Ltd. Receives FDA Warning Letter
8. Medarex and Massachusetts Biologic Laboratories Announce Primary Objective Achieved in Phase 2 Trial of Monoclonal Antibody Combination for the Treatment of Clostridium difficile Associated Diarrhea (CDAD)
9. Romark Laboratories Announces Presentation of New Nitazoxanide Data at 59th Annual AASLD Meeting and 50th Anniversary IASL Meeting in San Francisco
10. Caraco Pharmaceutical Laboratories, Ltd. Reports Results for the Second Quarter and First Six Months of Fiscal 2009
11. Phenomix and Forest Laboratories to Collaborate on Development and Commercialization of Dutogliptin in Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... , June 23, 2016 Apellis ... Phase 1 clinical trials of its complement C3 ... single and multiple ascending dose studies designed to ... (PD) of subcutaneous injection in healthy adult volunteers. ... (SC) either as a single dose (ranging from ...
(Date:6/23/2016)... 2016 Andrew D ... http://doi.org/10.17925/OHR.2016.12.01.22 Published recently in ... from touchONCOLOGY, Andrew D Zelenetz , discusses ... care is placing an increasing burden on healthcare ... therapies. With the patents on many biologics expiring, ...
(Date:6/23/2016)... ... June 23, 2016 , ... ... the Pennsylvania Convention Center and will showcase its product’s latest features from June ... be presenting a scientific poster on Disrupting Clinical Trials in The Cloud during ...
(Date:6/23/2016)... ... 23, 2016 , ... Velocity Products, a division of Morris ... optimized exclusively for Okuma CNC machining centers at The International Manufacturing Technology Show, ... several companies with expertise in toolholding, cutting tools, machining dynamics and distribution, Velocity ...
Breaking Biology Technology:
(Date:6/1/2016)... 2016 Favorable Government Initiatives Coupled ... Criminal Identification to Boost Global Biometrics System Market Through ... Research report, " Global Biometrics Market By Type, ... Opportunities, 2011 - 2021", the global biometrics market is ... account of growing security concerns across various end use ...
(Date:5/9/2016)... DUBAI , UAE, May 9, 2016 ... choice when it comes to expanding freedom for high ... Even in today,s globally connected world, there ... online conferencing system could ever duplicate sealing your deal ... are obtaining second passports by taking advantage of citizenship ...
(Date:4/26/2016)... DUBLIN , April 27, 2016 ... of the  "Global Multi-modal Biometrics Market 2016-2020"  report ... ) , The analysts forecast ... a CAGR of 15.49% during the period 2016-2020.  ... a number of sectors such as the healthcare, ...
Breaking Biology News(10 mins):